A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers

被引:3
作者
Epstein, Rachel L. [1 ,2 ,8 ]
Pramanick, Tannishtha [3 ]
Baptiste, Dimitri [3 ]
Buzzee, Benjamin [3 ]
Reese, Peter P. [4 ,5 ]
Linas, Benjamin P. [1 ,6 ]
Sawinski, Deirdre [7 ]
机构
[1] Boston Univ, Sch Med, Dept Med, Sect Infect Dis, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Pediat, Sect Infect Dis, Boston, MA 02118 USA
[3] Boston Med Ctr, Sect Infect Dis, Boston, MA USA
[4] Univ Penn, Perelman Sch Med, Dept Med, Renal Electrolyte Hypertens Div, Philadelphia, PA USA
[5] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA USA
[6] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[7] Weill Cornell Coll Med, Dept Nephrol & Transplantat, New York, NY USA
[8] Boston Univ, Sch Med, Crosstown Ctr, 801 Massachusetts Ave, 2nd Floor, Boston, MA 02118 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2023年 / 34卷 / 02期
关键词
hepatitis; economic analysis; epidemiology and outcomes; chronic hemodialysis; cost-benefit analysis; health policy catalyst; QUALITY-OF-LIFE; UNITED-STATES; INJECT DRUGS; PRIMARY-CARE; HCV; INFECTION; RNA; MORTALITY; DIALYSIS; SURVEILLANCE;
D O I
10.1681/ASN.2022030245
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background National guidelines recommend twice-yearly hepatitis C virus (HCV) screening for patients receiving in-center hemodialysis. However, studies examining the cost-effectiveness of HCV screening methods or frequencies are lacking.Methods We populated an HCV screening, treatment, and disease microsimulation model with a cohort representative of the US in-center hemodialysis population. Clinical outcomes, costs, and cost-effectiveness of the Kidney Disease Improving Global Outcomes (KDIGO) 2018 guidelines-endorsed HCV screening frequency (every 6 months) were compared with less frequent periodic screening (yearly, every 2 years), screening only at hemodialysis initiation, and no screening. We estimated expected quality adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) between each screening strategy and the next less expensive alternative strategy, from a health care sector perspective, in 2019 US dollars. For each strategy, we modeled an HCV outbreak occurring in 1% of centers. In sensitivity analyses, we varied mortality, linkage to HCV cure, screening method (ribonucleic acid versus antibody testing), test sensitivity, HCV infection rates, and outbreak frequencies.Results Screening only at hemodialysis initiation yielded HCV cure rates of 79%, with an ICER of $82,739 per QALY saved compared with no testing. Compared with screening at hemodialysis entry only, screening every 2 years increased cure rates to 88% and decreased liver-related deaths by 52%, with an ICER of $140,193. Screening every 6 months had an ICER of $934,757; in sensitivity analyses using a willingness-to-pay threshold of $150,000 per QALY gained, screening every 6 months was never cost-effective.Conclusions The KDIGO-recommended HCV screening interval (every 6 months) does not seem to be a cost-effective use of health care resources, suggesting that re-evaluation of less-frequent screening strategies should be considered.
引用
收藏
页码:205 / 219
页数:15
相关论文
共 64 条
[1]  
AASLD-IDSA HCV Guidance Panel, 2018, CLIN INFECT DIS, V67, P1477, DOI DOI 10.1093/CID/CIY585
[2]  
[Anonymous], 2001, MMWR Recomm Rep, V50, P1
[3]  
[Anonymous], Telekom
[4]  
[Anonymous], CHRON KIDN DIS SURV
[5]  
[Anonymous], Recommendations for testing, managing and treating hepatitis C
[6]   Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study [J].
Assoumou, Sabrina A. ;
Nolen, Shayla ;
Hagan, Liesl ;
Wang, Jianing ;
Yazdi, Golnaz Eftekhari ;
Thompson, William W. ;
Mayer, Kenneth H. ;
Puro, Jon ;
Zhu, Lin ;
Salomon, Joshua A. ;
Linas, Benjamin P. .
AMERICAN JOURNAL OF MEDICINE, 2020, 133 (11) :E641-E658
[7]   HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic [J].
Assoumou, Sabrina A. ;
Wang, Jianing ;
Nolen, Shayla ;
Yazdi, Golnaz Eftekhari ;
Mayer, Kenneth H. ;
Puro, Jon ;
Salomon, Joshua A. ;
Linas, Benjamin P. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (05) :1477-1483
[8]   Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons [J].
Assoumou, Sabrina A. ;
Tasillo, Abriana ;
Vellozzi, Claudia ;
Yazdi, Golnaz Eftekhari ;
Wang, Jianing ;
Nolen, Shayla ;
Hagan, Liesl ;
Thompson, William ;
Randall, Liisa M. ;
Strick, Lara ;
Salomon, Joshua A. ;
Linas, Benjamin P. .
CLINICAL INFECTIOUS DISEASES, 2020, 70 (07) :1388-1396
[9]   Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings [J].
Assoumou, Sabrina A. ;
Tasillo, Abriana ;
Leff, Jared A. ;
Schackman, Bruce R. ;
Drainoni, Mari-Lynn ;
Horsburgh, C. Robert ;
Barry, M. Anita ;
Regis, Craig ;
Kim, Arthur Y. ;
Marshall, Alison ;
Saxena, Sheel ;
Smith, Peter C. ;
Linas, Benjamin P. .
CLINICAL INFECTIOUS DISEASES, 2018, 66 (03) :376-384
[10]   Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study [J].
Barocas, Joshua A. ;
Savinkina, Alexandra ;
Lodi, Sara ;
Epstein, Rachel L. ;
Bouton, Tara C. ;
Sperring, Heather ;
Hsu, Heather E. ;
Jacobson, Karen R. ;
Schechter-Perkins, Elissa M. ;
Linas, Benjamin P. ;
White, Laura F. .
CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) :E1112-E1119